#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hepato-lenticular degeneration Acute lymphocytic leukaemia Retinal artery occlusion Adrenocortical carcinoma Cardiac arrest Proteus syndrome Adenovirus infection Small cell lung cancer extensive stage Chordoma Meningitis meningococcal Selective polysaccharide antibody deficiency Hepatic cirrhosis Peritoneal mesothelioma malignant Laryngeal squamous cell carcinoma Neuroendocrine cell hyperplasia of infancy More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis III – Trials in Disease Ornithine transcarbamoylase deficiency – Diagnostics Atypical teratoid/rhabdoid tumour of CNS – Treatment Focal segmental glomerulosclerosis – Basic Information Indolent systemic mastocytosis – Life with Disease Haemophilia A with anti factor VIII – Basic Information Acquired haemophilia – Treatment Antithrombin III deficiency – Treatment Idiopathic pulmonary fibrosis – Diagnostics Lymphatic malformation – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Telitacicept Quc398 Isis 678354 Sodium Salt Carbasalate Calcium Vortioxetine Hydrobromide Oxybutynin Amg 193 Ascorbic Acid Bp Abc-23A-116 L-Lysine Acetate Macrogol 3350 Neob Hydrocortisone Ph. Eur. Cedazuridine Ropivacaine Kan-101 Elezanumab Emraclidine Epoetin Alfa Losmapimod More therapies…

    Learn about Your Condition

    Glomerulonephritis chronic Retinal vein occlusion Gastrointestinal carcinoma Hypoglycaemia Actinic cheilitis Peripheral artery thrombosis Muscular dystrophy Hypophosphatasia Delirium Vaginal haemorrhage Peripheral ischaemia Hypotension Muscle hypertrophy Pemphigus Pemphigoid More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Total-Body PET with [18F]Flutemetamol in Patients with Post-COVID Syndrome (Long COVID)

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Post-acute COVID-19 syndrome
    Investigated Drugs:
    • Flutemetamol (18F)
    The Netherlands

  • RO7795068 for Weight Loss in Adults With Obesity or Overweight Without Type 2 Diabetes

    Recruiting

    3 1
    Investigated Diseases:
    • Obesity
    Belgium Czechia France Germany Hungary Italy +3

  • A study to evaluate the effect of nolasiban on uterine contractions in women undergoing IVF or ICSI treatments

    Recruiting

    2 1
    Spain

  • Long-Term Safety and Efficacy of Lebrikizumab in Children and Adolescents With Moderate-to-Severe Atopic Dermatitis

    Recruiting

    3 1
    Investigated Diseases:
    • Eczema
    • Dermatitis atopic
    Investigated Drugs:
    • Lebrikizumab
    Czechia France Germany Poland Spain

  • Early Stopping of Antibiotic Treatment in Children with Cancer and Febrile Neutropenia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Bacterial infection
    Investigated Drugs:
    • Amikacin
    • Cefepime
    • Ciprofloxacin
    Spain

  • Zanidatamab, tucatinib, capecitabine or eribulin mesylate in HER2-positive advanced breast cancer in adults

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    • Breast cancer
    Investigated Drugs:
    • Loperamide Hydrochloride
    • Tucatinib
    • Eribulin Mesylate
    Spain
Previous Page
1 … 17 18 19 20 21 … 1,645
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!